Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection

Mendizabal, Manuel; Ridruejo, Ezequiel; Piñero, Federico; Anders, Margarita; Padilla, Martín; Toro, Luis G.; Torre, Aldo; Montes, Pedro; Urzúa, Alvaro; Ballerga, Esteban Gonzalez; Silveyra, María Dolores; Michelato, Douglas; Díaz, Javier; Peralta, Mirta; Pages, Josefina; García, Sandro Ruiz; Lozano, Isabel Gutierrez; Macias, Yuridia; Cocozzella, Daniel; Chavez-Tapia, Norberto; Tagle, Martín; Dominguez, Alejandra; Varón, Adriana; Pozo, Emilia Vera; Tijera, Fátima Higuera-de la; Bustios, Carla; Conte, Damiá; Escajadillo, Nataly; Gómez, Andrés J; Tenorio, Laura; Barradas, Mauricio Castillo; Schinoni, Maria Isabel; Bessone, Fernando; Contreras, Fernando; Nazal, Leyla; Sanchez, Abel; García, Matías; Brutti, Julia; Cabrera, María Cecilia; Miranda-Zazueta, Godolfino; Rojas, German; Cattaneo, Maximo; Castro-Narro, Graciela; Rubinstein, Fernando; Silva, Marcelo O.

INTRODUCTION AND OBJECTIVES: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. PATIENTS: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. RESULTS: Overall, 4.6%(CI 3.7-5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14-25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1(CI 1.9-4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). CONCLUSIONS: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIF-C had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380.